The aim of this study was to evaluate and compare the serum concentrations of LRP6, SFRP3, and DVL1 between patients with neuroendocrine tumors (NETs) and healthy individuals, and to correlate these findings with selected demographic, clinicopathological, and biochemical characteristics. This evidence concerns the gene FRZB and neuroendocrine neoplasm.